Skip to main content
JNJ
NYSE Life Sciences

强生公司的Nipocalimab获得FDA快速通道指定用于系统性红斑狼疮

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$246.046
Mkt Cap
$599.004B
52W Low
$141.5
52W High
$251.71
Market data snapshot near publication time

summarizeSummary

强生公司的治疗药物Nipocalimab已被授予美国FDA快速通道指定用于系统性红斑狼疮（SLE）。此指定具有重要意义，因为它旨在加速治疗严重疾病和解决未满足的医疗需求的药物的开发和审查。对于强生公司来说，这加速了Nipocalimab在其产品线中的潜在上市路径，通过促进与FDA更频繁的互动和潜在的滚动审查。虽然这不是批准，但它表明监管机构对该药物的潜力有信心，并可能降低其开发风险，使其成为该公司制药部门的积极催化剂。投资者现在将关注进一步的临床试验进展和随后的监管里程碑。

在该公告发布时，JNJ的交易价格为$246.05，交易所为NYSE，所属行业为Life Sciences，市值约为$5990亿。 52周交易区间为$141.50至$251.71。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Imaavy Secures FDA Priority Review for Rare Blood Disorder
Sentiment: Positive
View Wiseek Article
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
Sentiment: Positive
View Wiseek Article
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
J&J Reports Strong Q1 Operational Sales Growth, Raises Dividend Amidst Talc Litigation Challenges and Increased Net Debt
Sentiment: Neutral
View Wiseek Article
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
Sentiment: Positive
View Wiseek Article
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
Sentiment: Negative
View Wiseek Article
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato
Sentiment: Positive
View Wiseek Article
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
Sentiment: Neutral
View Wiseek Article
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Sentiment: Positive
View Wiseek Article